INOCURE SRO

Their core work

Inocure is a Czech technology SME specializing in electrospun nanofiber scaffolds and 3D cell culture platforms for biomedical and pharmaceutical applications. They manufacture nanostructured materials used as tissue engineering scaffolds, drug delivery carriers, and organ-on-chip substrates, serving as a technology provider to academic and clinical research consortia across Europe. Their core commercial product line centers on eliminating animal testing in pharmaceuticals through biomimetic 3D culture systems, as evidenced by their DifMATRIX project. They also apply their nanoparticle and controlled-release expertise to non-pharma sectors including veterinary nutrition and smart wound care.

What they specialise in

How they've shifted over time

Inocure's early H2020 work (2016–2018) focused on fundamental nanoparticle and controlled-release technologies with applications in animal feed (NanoFEED) and brown adipose tissue research (nanoBAT), alongside translational medicine training (transMed). From 2019 onward, they shifted decisively toward biomedical applications — iPSC-based tissue engineering, organ-on-chip platforms, cancer immunotherapy delivery, and smart wound dressings. Their most recent projects (2021–2025) show convergence on advanced in-vitro models: Heart-on-Chip (EMAPS-Cardio), drug screening platforms (ActiTOX), and sustainable biomaterials (CELISE), signaling a maturing company moving from material science supplier to integrated biomedical platform provider.

Inocure is evolving from a nanofiber materials supplier into a biomedical platform company focused on in-vitro tissue models that replace animal testing — a market with strong regulatory tailwinds in the EU.

How they like to work

Inocure operates almost exclusively as a specialist partner (10 of 11 projects), contributing their nanofiber and scaffold manufacturing capabilities to larger consortia. Their single coordination (DifMATRIX, an SME Instrument Phase 1) was a feasibility study for their own product, not a consortium-led effort. With 91 unique partners across 34 countries and heavy participation in MSCA mobility schemes (8 of 11 projects), they function as a high-connectivity technology node — hosting visiting researchers and providing materials/platforms rather than leading scientific agendas.

Inocure has built a remarkably wide network for an SME: 91 unique consortium partners spanning 34 countries, driven largely by MSCA-RISE staff exchange programs that connect them to universities and research institutes worldwide. Their geographic reach extends well beyond Europe through these mobility networks.

What sets them apart

Inocure occupies a rare niche as a commercial SME that can manufacture research-grade nanofiber scaffolds and integrate them into functional 3D culture systems — bridging the gap between academic material science and pharmaceutical industry needs. Their MSCA-heavy portfolio means they are deeply embedded in researcher training networks, giving them early access to emerging biomedical applications. For consortium builders, they offer something hard to find: a private company with hands-on fabrication capability that is already trusted by 91 partners and comfortable operating in large international research teams.

Highlights from their portfolio

• DifMATRIX
  Their only coordinated project — an SME Instrument feasibility study for a 3D cell culture platform to replace animal testing, revealing their core commercial ambition.
• EMAPS-Cardio
  Their largest funded project (EUR 435K) and most technically advanced: electroactive polymer scaffolds for Heart-on-Chip, representing their move into organ-on-chip territory.
• I-DireCT
  Highest single-project funding (EUR 470K) in cancer immunotherapy delivery — demonstrates their nanoparticle formulation capabilities applied to oncology.